Phase 1 N=48 Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=36 Aspirin Dosing in Diabetic Patients
Type 2 Diabetes Mellitus · Coronary Artery Disease
Primary: Collagen Induced Aggregation — 32 percentage of platelet aggregation
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Phase 2 N=55 Antiplatelet Therapy in HIV
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
Phase 4 N=302 Clopidogrel and Aspirin Interaction Study-2
Drug Action Increased
Primary: Blood Concentration of the Active Metabolite of Clopidogrel — 14.45; 13.80 ng/ml — p=0.66
N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Early Phase 1 N=92 Aspirin Resistance in Coronary Artery Disease
Coronary Artery Disease
Primary: Change in Serum Thromboxane B2 — 5.02; 2.78 ng/mL — p=0.005
Phase 2 N=40 Effects of Pioglitazone on Platelet Function
Diabetes · Platelet Function · Healthy
Primary: Percent Platelet Aggregation Induced by Arachidonic Acid — 80; 90; 60; 29 maximum percentage aggregation
N/A N=15 Aspirin Responsiveness in Women With Coronary Artery Disease
CAD
Primary: Women With Known CAD Who Are Hyporesponsive to Low Dose (81 mg) Aspirin — 0 participants
Phase 4 N=34 Pharmacogenomics of Antiplatelet Response
Atherosclerosis
Primary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005
Phase 4 N=72 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Acute Coronary Syndrome
Primary: Assess Inflammatory Response to Intravenous Endotoxin — 167.53; 111.05; 254.92; 128.73 pg/ml
Phase 2 N=36 Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Stable Angina
Primary: Number of Participants With Elevation of Cardiac Enzyme — 4; 2 Participants
Phase 3 N=76 Chronic Kidney Disease (CKD) Platelet Study
Chronic Kidney Diseases · Heart Attack · Stroke, Ischemic
Primary: ADP Induced Platelet Aggregation — 0; 6; 1 ohms — p=0.002
Phase 1 N=102 Naproxen Sodium/ASA Platelet Study
Hematology
Primary: Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration — 93.09; 87.71; 92.87; 98.72 percentage
Phase 4 N=33 Pharmacogenomics of Antiplatelet Response - II (PARes-II)
Atherothrombosis
Primary: Changes in Platelet Transcriptome — 77.1 FPKM difference for HBG1 Gene
Phase 4 N=101 Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Diabetes Mellitus, Type 2 · Coronary Artery Disease
Primary: P2Y12 Reaction Units (PRU) — 47; 136; 39 PRU
N/A N=504 Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Coronary Artery Disease
Primary: Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy as a Result of Whole Blood Aggregometry Testing (See Outcome Measure Description)…
Phase 2 N=27 The Effects of Omega-3 Fatty Acids on Aspirin Resistance
Increased Drug Resistance
Primary: the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment — 0.0; 10.9; -6.5; 30.5 seconds — p=0.00
Phase 4 N=244 Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
Cerebral Infarction
Primary: Aspirin Resistance (ARU ≥ 550) — 9; 11 participants — p=0.654
Phase 2 N=15 Anti-Platelets in Chronic Obstructive Pulmonary Disease
COPD · Emphysema · Emphysema or COPD
Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84
N/A N=132 Genotypic and Phenotypic Correlates of Resistance to Aspirin
Platelet Dysfunction Due to Aspirin
Primary: Whole Blood Coagulation — 453.8 Aspirin response units (ARU)
N/A N=9 Pharmacological Study That Measures Omeprazole Effect on Aspirins Absorption in Healthy Volunteers
Aspirin Blood Level · Proton Pump Inhiditor Treatment
Primary: Aspirin Level in Blood (Area Under the Curve) — 49.4; 50.7; 8.7; 6.5 mg*hour/mL
Phase 2 N=27 Targeting Platelets in Chronic HIV Infection
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Phase 4 N=70 Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
Cardiovascular Diseases · Metabolic Syndrome X · Atherosclerosis
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months — 27.6; 27.0; 31.4; 25.7 ng/mL
Phase 4 N=36 Aspirin Responsiveness in Women at Risk for Cardiac Events
Heart Disease
Primary: Number of Women Aspirin Resistant — 3 participants
Phase 2 N=50 Clopidogrel Pharmacogenomics Project
Disease Susceptibility
Primary: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230 — 30; 18 Number of Patients with PRU>230 — p==0.02
Phase 4 N=37 Aspirin Dose and Atherosclerosis in Patients With Heart Disease
Cardiovascular Diseases · Atherosclerosis · Myocardial Infarction
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months. — 10.0; 11.2; 10.0; 11.0 ng/mL
Phase 2 N=208 Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia
Pre-Eclampsia
Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio
Phase 2 N=46 Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
Asthma, Aspirin-Induced · Aspirin Exacerbated Asthma
Primary: Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo — 79; 139 mg
Phase 2 N=57 Thromboxane Receptor Antagonist to Improve Endothelial Function
Cardiovascular Diseases · Vascular Dilation
Primary: Change in Reactive Hyperemia Index (RHI) — -0.01; 0.21 percentage index change